SSA
PRQR icon

Schonfeld Strategic Advisors’s ProQR Therapeutics PRQR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-412,190
Closed -$750K – 2307
2024
Q3 		$750K Buy
412,190
+350,290
+566% +$658K 0.01% 1262
2024
Q2 		$103K Buy
+61,900
New +$120K ﹤0.01% 1888
2021
Q2 		– Sell
-23,200
Closed -$153K – 2225
2021
Q1 		$153K Buy
23,200
+11,700
+102% +$59.8K ﹤0.01% 1572
2020
Q4 		$49K Buy
+11,500
New +$48.5K ﹤0.01% 1497

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Schonfeld Strategic Advisors's PRQR Position: Q4 2024 in Review

Schonfeld Strategic Advisors sold out of ProQR Therapeutics (PRQR) in Q4 2024, closing a stake of 412,190 shares — an estimated $750K sold.

Schonfeld Strategic Advisors first reported a position in PRQR in Q4 2020 and held it in 4 quarters. The position peaked at $750K in Q3 2024. 77 funds tracked by Wall St. Rank hold PRQR as of Q4 2024.

  • Schonfeld Strategic Advisors reported no remaining ProQR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 412,190 ProQR Therapeutics shares in Q4 2024, an estimated $750K.
  • Schonfeld Strategic Advisors first reported a position in ProQR Therapeutics in Q4 2020 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's ProQR Therapeutics position peaked at $750K in Q3 2024.
  • 77 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.